Objective  To establish the drug use evaluation (DUE) criteria of recombinant human prourokinase (rhPro-UK), and to provide reference for the rational clinical application of rhPro-UK.

Methods  Based on the drug instructions of rhPro-UK, DUE standard rules were established by referring to relevant guidelines, expert consensus, authoritative literature and expert consultation. The medical records of hospitalized patients treated with rhPro-UK from January 2019 to May 2022 in Xilin Gol League Central Hospital were evaluated by retrospective investigation. The effectiveness of rhPro-UK was evaluated based on clinical outcome, and its safety was evaluated based on the incidence and severity of adverse reactions.

Results  A total of 230 cases were included, and 4 cases fully met the evaluation criteria (medication indication, medication process, medication results), accounting for 1.74%. There were 226 patients (98.26%) with irrational drug use, mainly manifested in two aspects of drug indication and drug process ( administration mode and dosage). Treatment was effective in 221 patients, with an overall effective rate of 96.09%; 139 patients experienced adverse reactions, with an incidence rate of 60.43%.

Conclusion  The clinical use of rhPro-UK in our hospital is irrational in the indication of medication and the process of medication, and the establishment of the DUE standard rules of rhPro-UK can provide a reference to standardize the clinical application of rhPro-UK and promote its rational use.

1.国家卫生计生委合理用药专家委员会, 中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11(1): 40-65. DOI: 10.12037/YXQY.2019.01-07.

2.国家药品监督管理局. 注射用重组人尿激酶原(普佑克®)说明书[DB/OL]. (2021-04-28) [2023-03-15]. https://zy.yaozh.com/instruct/sms20220223/37.pdf.

3.Jiang WL, Xiong XS, Du XH, et al. Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction[J]. Coron Artery Dis, 2021, 32(1): 25-30. DOI: 10.1097/MCA.0000000000000898.

4.Huang D, Qian JY, Liu ZJ, et al. Effects of intracoronary pro-urokinase or tirofiban on coronary flow during primary percutaneous coronary intervention for acute myocardial infarction: a multi-center,placebo-controlled, single-blind,randomized clinical trial[J]. Front Cardiovasc Med, 2021, 8: 710994. DOI: 10.3389/fcvm.2021.710994.

5.林东升, 傅广, 何仲春, 等. 冠状动脉内联合应用重组人尿激酶原和替罗非班对行急诊PCI的STEMI患者心肌血流灌注的影响[J]. 临床心血管病杂志, 2021, 37(3): 215-219. [Lin DS, Fu G, He ZC, et al. Effects of intracoronary low-dose recombinant human prourokinase and tirofiban on myocardial perfusion in STEMI patients with primary PCI[J]. Journal of Clinical Cardiology, 2021, 37(3): 215-219.] DOI: 10.13201/j/issn.1001-1439.2021. 03.006.

6.张正光, 肖成祖, 胡显文, 等. 国产重组人尿激酶原的药效学、药理学和毒理学研究[J]. 中国科学: 生命科学, 2011, 41(10): 1024-1029. [Zhang ZG, Xiao CZ, Hu XW, et al. Overwiew of investigation of pharmacodynamics, pharmacology, and toxicology of domestic human prourokinase[J]. Scientia Sinica (Vitae), 2011, 41: 1024-1029.] DOI: 10.1360/052011-593.

7.Afanasjeva J, Burk M, Cunningham FF, et al. ASHP Guidellines on medication-use evaluation[J]. Am J Health Syst Pharm, 2021, 78(2): 168-175. DOI: 10.1093/ajhp/zxaa393.

8.袁浩宇, 林勇, 胡明, 等. 药物利用评价标准建立的方法探讨及实践[J]. 中国药房, 2010, 21(22): 2101-2104. [Yuan HY, Lin Y, Hu M, et al. Exploration on the method for establishment of DUE standard and practical study[J]. China Pharmacy, 2010, 21(22): 2101-2104.] DOI: CNKI: SUN:ZGYA.0.2010-22-036.

9.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766-783. DOI: 10.3760/cma.j.iss-n.0253-3758.2019.10.003.

10.国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2018, 10(6): 1-130. DOI: 10.12037/YXQY. 2018.06-01.

11.姚朱华, 陈湾湾, 曹明英, 等. 注射用重组人尿激酶原治疗急性ST段抬高型心肌梗死的疗效和安全性及影响因素分析[J]. 中国全科医学, 2016, 9: 1061-1066. [Yao ZH, Chen WW, Cao MY, et al. Efficacy and safety of injection of recombinant human prourokinase in the treatmentof acute ST-segment elevation myocardial infarction and influencing factors[J]. Chinese General Practice, 2016, 19(9): 1061-1066.] DOI: 10.3969/j.issn. 1007-9572.2016.09.016.

12.中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004

13.中华医药生物技术协会药物性肝损伤防治技术专业专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2023, 31(4): 355-384. DOI: 10.3760/cma.j.cn501113-20230419-00176.

14.颜红兵, 向定成, 刘红梅, 等. ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识[J]. 中国介入心脏病学杂志, 2018, 26(4): 181-190. [Yan HB, Xiang DC, Liu HM, et al. Chinese expert consensus on pre-hospital thrombolytic therapy for ST segment elevation acute myocardial infarction[J]. Chinese Journal of Interventional Cardiology, 2018, 26(4): 181-190.] DOI: 10.3969/j.issn. 1004-8812.2018.04.001.

15.林小娟, 黄小红, 黄涓涓, 等. 利伐沙班药物利用评价标准的建立与应用[J]. 中国现代应用药学, 2020, 37(20): 2543-2548. [Lin XJ, Huang XH, Huang JJ, et al. Establishment and application of drug yse evaluation standard of rivaroxaban[J]. Chinese Journal of Modern Applied Pharmacy, 2020, 37(20): 2543-2548.] DOI: 10. 13748/j.cnki.issn1007-7693.2020.20.020.

16.李小东, 居靖, 李令培, 等. 阿替普酶治疗急性缺血性脑卒中药物利用评价标准的建立与应用[J]. 中国药师, 2021, 24(7): 323-326. [Li XD, Ju J, Li LP, et al. Establishment and application of evaluation criteria for the utilization of alteplase in the treatment of acute ischemic stroke[J]. China Pharmacist, 2021, 24(7): 323-326.] DOI: 10.19962/j.cnki.issn1008-049X.2021.07.023.

17.Fan G, Wu XG, Jiao WP, et al. Safety and efficacy of intracoronary recombinant human prourokinase administration in patients with acute myocardial infarction and ST-segment elevation: A meta-analysis of randomized controlled trials[J]. Exp Ther Med, 2023, 25(1): 40. DOI: 10.3892/etm.2022.11739.

18.Geng YX, Zhao LY, Wang Y, et al. Competency model for dentists in China: Results of a Delphi study[J]. PLoS One, 2018, 13(3): e0194411. DOI: 10.1371/journal.pone. 0194411.

19.彭贵琴, 刘文华, 唐宗伟, 等. 基于德尔菲法构建我国癌痛规范化药学服务的指标体系[J]. 药物流行病学杂志, 2021, 30(8): 562-566. [Peng GQ, Liu WH, Tang ZW, et al. Construction of an index system of standardized pharmaceutical care for cancer pain in China: A delphi study[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(8): 562-566.] DOI: 10.19960/j.cnki.issn1005-0698. 2021.08.013.

20.原国家食品药品监督管理局药品安全监管司, 国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[S]. 2012.

21.薛逸非, 李光耀, 张弨. 临床超说明书用药的分析[J]. 中国临床药理学杂志, 2021, 37(17): 2360-2363. [Xue YF, Li GY, Zhang C, et al. Analysis of clinical off-label drug use[J]. The Chinese Journal of Clinical Pharmacology, 2021, 27(17): 2360-2363.] DOI: 10.13699/j.cnki. 1001-6821.2021.17.028.

22.Zhang YR, Huang ZQ. Efficacy analysis of recombinant human pro-urokinase combined with percutaneous coronary intervention in the treatment of acute ST-segment elevation myocardial infarction[J]. WRSJ, 2021, 7(11): 310-314. DOI: 10.6911/WSRJ.202111_7(11).0045.

23.张镭, 谭玲, 陆进. 超说明书用药专家共识[J]. 药物不良反应杂志, 2015, 17(2): 101-103. [Zhang L, Tan L, Lu J. Expert consensus on off-label drug use[J]. Adverse Drug Reactions Journal,2015, 17(2): 101-103.] DOI: 10.3760/cma.j.issn.1008-5734.2015.02.011.

24.广东省药学会. 医疗机构超药品说明书用药管理专家共识[J]. 中国现代应用药学, 2017, 34(3): 436-438. DOI: 10.13748/j.cnki.issn1007-7693.2017.03.031.

25.田彩霞, 田云霞, 薛伟珍, 等. 重组人尿激酶原联合替罗非班治疗急性ST段抬高型心肌梗死急诊PCI的疗效观察[J]. 中西医结合心脑血管病杂志, 2021, 19(8): 1406-1408. [Tian CX, Tian YX, Xue WZ, et al. Curative effect of recombinant human urokinase combined with Tirofiban in the treatment of acute ST-segment elevation myocardial infarction by emergency PCI[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2021, 19(8): 1406-1408.] DOI: 10.12101/j.issn.1672-1349.2021.08.042.

26.张帅, 王要鑫, 刘洁云. 重组人尿激酶原联合比伐芦定治疗急性ST段抬高型心肌梗死PCI术中无复流/慢血流的临床疗效[J]. 中西医结合心脑血管病杂志, 2022, 20(4): 763-765. [Zhang S, Wang YX, Liu JY. Clinical efficacy of recombinant human urokinase combined with bivarudine in the treatment of acute ST-segment elevation myocardial infarction without reflow/slow flow after PCI[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2022, 20(4): 763-765.] DOI: 10.12102/j.issn.1672-1349.2022.04.041.

27.白文楼, 陈涛, 孟存良, 等. 比伐芦定联合重组人尿激酶原对老年急性心肌梗死患者直接PCI术后慢血流/无复流的影响及安全性[J]. 临床心血管病杂志, 2019, 35(7): 595-599. [Bai WL, Chen T, Meng LC, et al. Effect and safety of bivalrudine combined with recombinant human prourokinase on slow/no-refolw after emergency PCI in elderly patients with acute myocardial infarction[J]. Journal of Clinical Cardiology, 2019, 35(7): 595-599.] DOI: 10.13201/j.issn.1001-1439.2019.07.004.

28.曾敬, 张小群, 温春兰, 等. 比伐芦定联合替罗非班用于急性心肌梗死急诊PCI术的疗效及出血风险评估[J]. 中国药业, 2018, 27(17): 40-42. [Zeng J, Zhang XQ, Wen CL, et al. Effect and bleeding risk assessment of bivalirudin combined with tirofiban used in emergency percutaneous coronary intervention for patients with acute myocardial infarction[J]. China Pharmaceuticals, 2018, 27(17): 40-42.] DOI: 10.3969/j.issn.1006-4931.2018.17.011.

29.0n of myocardial markers in patients with acute myocardial infarction and their relationship with prognosis[J]. Chinese Journal of Clinical Pathologist, 2020, 12(2): 95-99.] DOI: 10.3969/j.issn.1674-7151. 2020.02.009.